| [1] |
Carey L A,Perou C M,Livasy C A,et al.Race,breast cancer subtypes,and survival in the Carolina Breast Cancer Study.JAMA,2006,295:2492-2502.
|
| [2] |
Perou C M,Sørlie T,Eisen M B,et al.Molecular portraits of human breast tumours.Nature,2000,406:747-752.
|
| [3] |
Sorlie T,Perou C M,Tibshirani R,et al.Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications.Proc Natl Acad Sci USA,2001,98:10 869-10 874.
|
| [4] |
Sorlie T,Tibshirani R,Parker J,et al.Repeated observation of breast tumor subtypes in independent gene expression data sets.Proc Natl Acad Sci USA,2003,100:8418-8423.
|
| [5] |
Ihemelandu C U,Leffall L D Jr,Dewitty R L,et al.Molecular breast cancer subtypes in premenopausal and postmenopausal African-American women:age-specific prevalence and survi-val.J Surg Res,2007,143:109-118.
|
| [6] |
Adebamowo C A,Famooto A,Ogundiran T O,et al.Immunohistochemical and molecular subtypes of breast cancer in Nigeria.Breast Cancer Res Treat,2008,110:183-188.
|
| [7] |
Dent R,Trudeau M,Pritchard K I,et al.Triple-negative breast cancer:clinical features and patterns of recurrence.Clin Cancer Res,2007,13:4429-4434.
|
| [8] |
Ihemelandu C U,Naab T J,Mezghebe H M,et al.Basal cell-like(triple-negative)breast cancer,a predictor of distant metastasis in African American women.Am J Surg,2008,195:153-158.
|
| [9] |
Haffty B G,Yang Q,Reiss M,et al.Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer.J Clin Oncol,2006,24:5652-5657.
|
| [10] |
Bauer K R,Brown M,Cress R D,et al.Descriptive analysis of estrogen receptor(ER)-negative,progesterone receptor(PR)-negative,and HER-2-negative invasive breast cancer,the so-called triple-negative phenotype:a population-based study from the California cancer Registry.Cancer,2007,109:1721-1728.
|
| [11] |
Smith I,Procter M,Gelber R D,et al.2-year follow-up of trastuzumab after adjuvant chemotherapy in HER-positive breast cancer:a randomized controlled trial.Lancet,2007,369:29-36.
|
| [12] |
Romond E H,Perez E A,Bryant J,et al.Trastuzumab plus adjuvant chemotherapy for operable HER-2-positive breast cancer.N Engl J Med,2005,353:1673-1684.
|
| [13] |
Bertucci F,Finetti P,Cervera N,et al.How basal are triple-negative breast cancers?Int J Cancer,2008,123:236-240.
|
| [14] |
Carey L A,Dees E C,Sawyer L,et al.The triple negative paradox:primary tumor chemosensitivity of breast cancer subtypes.Clin Cancer Res,2007,13:2329-2334.
|